APO RESEARCH · REPORT
Heart Failure Drugs
Heart failure occurs when your heart muscle doesn't pump blood as well as it should.
Product & engineering
Understand the product.
Heart failure occurs when your heart muscle doesn't pump blood as well as it should.
Selected research
Market Structure
Global Heart Failure Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Heart failure occurs when your heart muscle doesn't pump blood as well as it should.
The market is concentrated as Novartis, Pfizer, AstraZeneca , Hikma, Teva etc. Turkey is the largest consumption place in the Turkey and Middle East & Africa market, with a consumption market share nearly 21%.
This report provides an overview of the global Heart Failure Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Heart Failure Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Heart Failure Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Heart Failure Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Heart Failure Drugs Segment by Company
Novartis
Pfizer
AstraZeneca
Hikma
Teva
Cipla
Merck & Co.
Amgen
Roche
Sun Pharma
Mylan
Heart Failure Drugs Segment by Type
ACEI
Angiotensin II Receptor Blockers
ARNIs
Beta Blockers
Aldosterone Antagonists
Diuretics
Heart Failure Drugs Segment by Application
Reduced Ejection Fraction
Preserved Ejection Fraction
Heart Failure Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heart Failure Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Heart Failure Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heart Failure Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Heart Failure Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Heart Failure Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Heart Failure Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Heart Failure Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- ACEI
- Angiotensin II Receptor Blockers
- ARNIs
- Beta Blockers
- Aldosterone Antagonists
- Diuretics
Applications
- Reduced Ejection Fraction
- Preserved Ejection Fraction
Companies covered
- Novartis
- Pfizer
- AstraZeneca
- Hikma
- Teva
- Cipla
- Merck & Co.
- Amgen
- Roche
- Sun Pharma
- Mylan
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Heart Failure Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Heart Failure Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Heart Failure Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Heart Failure Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Heart Failure Drugs Market Dynamics
- 2.1 Heart Failure Drugs Industry Trends
- 2.2 Heart Failure Drugs Industry Drivers
- 2.3 Heart Failure Drugs Industry Opportunities and Challenges
- 2.4 Heart Failure Drugs Industry Restraints
3 Heart Failure Drugs Market by Manufacturers
- 3.1 Global Heart Failure Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Heart Failure Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Heart Failure Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Heart Failure Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Heart Failure Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Heart Failure Drugs Manufacturers, Product Type & Application
- 3.7 Global Heart Failure Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Heart Failure Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Heart Failure Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Heart Failure Drugs Tier 1, Tier 2, and Tier 3
4 Heart Failure Drugs Market by Type
- 4.1 Heart Failure Drugs Type Introduction
- 4.1.1 ACEI
- 4.1.2 Angiotensin II Receptor Blockers
- 4.1.3 ARNIs
- 4.1.4 Beta Blockers
- 4.1.5 Aldosterone Antagonists
- 4.1.6 Diuretics
- 4.2 Global Heart Failure Drugs Sales by Type
- 4.2.1 Global Heart Failure Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Heart Failure Drugs Sales by Type (2021-2032)
- 4.2.3 Global Heart Failure Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Heart Failure Drugs Revenue by Type
- 4.3.1 Global Heart Failure Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Heart Failure Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Heart Failure Drugs Revenue Market Share by Type (2021-2032)
5 Heart Failure Drugs Market by Application
- 5.1 Heart Failure Drugs Application Introduction
- 5.1.1 Reduced Ejection Fraction
- 5.1.2 Preserved Ejection Fraction
- 5.2 Global Heart Failure Drugs Sales by Application
- 5.2.1 Global Heart Failure Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Heart Failure Drugs Sales by Application (2021-2032)
- 5.2.3 Global Heart Failure Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Heart Failure Drugs Revenue by Application
- 5.3.1 Global Heart Failure Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Heart Failure Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Heart Failure Drugs Revenue Market Share by Application (2021-2032)
6 Global Heart Failure Drugs Sales by Region
- 6.1 Global Heart Failure Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Heart Failure Drugs Sales by Region (2021-2032)
- 6.2.1 Global Heart Failure Drugs Sales by Region (2021-2026)
- 6.2.2 Global Heart Failure Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Heart Failure Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Heart Failure Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Heart Failure Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Heart Failure Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Heart Failure Drugs Revenue by Region
- 7.1 Global Heart Failure Drugs Revenue by Region
- 7.1.1 Global Heart Failure Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Heart Failure Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Heart Failure Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Heart Failure Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Heart Failure Drugs Revenue (2021-2032)
- 7.2.2 North America Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Heart Failure Drugs Revenue (2021-2032)
- 7.3.2 Europe Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Heart Failure Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Heart Failure Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novartis
- 8.1.1 Novartis Company Information
- 8.1.2 Novartis Business Overview
- 8.1.3 Novartis Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis Heart Failure Drugs Product Portfolio
- 8.1.5 Novartis Recent Developments
- 8.2 Pfizer
- 8.2.1 Pfizer Company Information
- 8.2.2 Pfizer Business Overview
- 8.2.3 Pfizer Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Pfizer Heart Failure Drugs Product Portfolio
- 8.2.5 Pfizer Recent Developments
- 8.3 AstraZeneca
- 8.3.1 AstraZeneca Company Information
- 8.3.2 AstraZeneca Business Overview
- 8.3.3 AstraZeneca Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 AstraZeneca Heart Failure Drugs Product Portfolio
- 8.3.5 AstraZeneca Recent Developments
- 8.4 Hikma
- 8.4.1 Hikma Company Information
- 8.4.2 Hikma Business Overview
- 8.4.3 Hikma Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Hikma Heart Failure Drugs Product Portfolio
- 8.4.5 Hikma Recent Developments
- 8.5 Teva
- 8.5.1 Teva Company Information
- 8.5.2 Teva Business Overview
- 8.5.3 Teva Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Teva Heart Failure Drugs Product Portfolio
- 8.5.5 Teva Recent Developments
- 8.6 Cipla
- 8.6.1 Cipla Company Information
- 8.6.2 Cipla Business Overview
- 8.6.3 Cipla Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Cipla Heart Failure Drugs Product Portfolio
- 8.6.5 Cipla Recent Developments
- 8.7 Merck & Co.
- 8.7.1 Merck & Co. Company Information
- 8.7.2 Merck & Co. Business Overview
- 8.7.3 Merck & Co. Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Merck & Co. Heart Failure Drugs Product Portfolio
- 8.7.5 Merck & Co. Recent Developments
- 8.8 Amgen
- 8.8.1 Amgen Company Information
- 8.8.2 Amgen Business Overview
- 8.8.3 Amgen Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Amgen Heart Failure Drugs Product Portfolio
- 8.8.5 Amgen Recent Developments
- 8.9 Roche
- 8.9.1 Roche Company Information
- 8.9.2 Roche Business Overview
- 8.9.3 Roche Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Roche Heart Failure Drugs Product Portfolio
- 8.9.5 Roche Recent Developments
- 8.10 Sun Pharma
- 8.10.1 Sun Pharma Company Information
- 8.10.2 Sun Pharma Business Overview
- 8.10.3 Sun Pharma Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Sun Pharma Heart Failure Drugs Product Portfolio
- 8.10.5 Sun Pharma Recent Developments
- 8.11 Mylan
- 8.11.1 Mylan Company Information
- 8.11.2 Mylan Business Overview
- 8.11.3 Mylan Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Mylan Heart Failure Drugs Product Portfolio
- 8.11.5 Mylan Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Heart Failure Drugs Value Chain Analysis
- 9.1.1 Heart Failure Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Heart Failure Drugs Production Mode & Process
- 9.2 Heart Failure Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Heart Failure Drugs Distributors
- 9.2.3 Heart Failure Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst